St. Jude, Guidant Swap Distribution Rights Strategies With Investors
This article was originally published in The Gray Sheet
Executive Summary
Medical device start-ups seeking equity investments from larger firms should avoid signing over total distribution rights to their potential partners, according to Guidant
You may also be interested in...
Medinol Was Boston Scientific’s First And Final Pipeline Partner, CFO Vows
Boston Scientific is extracting a painful lesson from its failed business relationship with former stent partner Medinol: never delegate manufacturing and R&D authority to another firm
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.